Real World Evidence Clinical Utility Study of KidneyIntelX
Recruiting · NCT04802395
Conditions: Chronic Kidney Diseases, Diabetic Kidney Disease
At a glance
- Research payments reported, 2025
- $108,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 10,000
About the trial
- Sponsor
- Renalytix AI, Inc. (with Mount Sinai Hospital, New York)
- Tested
- KidneyIntelX (diagnostic_test)
- Dates
- Started 2021-03-02; completion 2026-12-01
- Results posted
- Not yet
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
From ClinicalTrials.gov, last updated 2026-08-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Renalytix Ai, Inc. reported $108,000 in research payments for this study in 2025 (3 payments).
Products named: Kidneyintelx Blood Collection Convenience Kit
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Icahn School of Medicine at Mount Sinai $108,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.